Meeting
2016 Gastrointestinal Cancers Symposium
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
Authors
May Thet Cho
Barnes Jewish Hospital, St. Louis, MO
May Thet Cho , Dean Lim , Timothy W. Synold , Paul Henry Frankel , Lucille A. Leong , Joseph Chao , Vincent M. Chung , Yuan Chen , Stephen Sentovich , Eloise Luevanos , Marwan Fakih
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02041481
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 679)
DOI
10.1200/jco.2016.34.4_suppl.679
Abstract #
679
Poster Bd #
J18
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2012 Gastrointestinal Cancers Symposium
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.
First Author: Li-Tzong Chen
Poster
2012 Gastrointestinal Cancers Symposium
Early outcome of a phase I study of interrupted pulse dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer.
First Author: Eric Roeland
Poster
2023 ASCO Annual Meeting
A phase 1/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC).
First Author: Jayesh Desai